Listar por autor "Teijeira, Lucía"
Mostrando ítems 1-2 de 2
-
Baseline circulating blood cell counts and ratios and changes therein for predicting immune-related adverse events during immune checkpoint inhibitor therapy: a multicenter, prospective, observational, pan-cancer cohort study with a gender perspective
Teijeira, Lucía; Martínez Kareaga, Mireia; Moreno, Amaia; Elejoste, Ibone de; Ibáñez Beroiz, B. ; Arrazubi, Virginia; Díaz de Corcuera, Isabela; Elejalde, Iñaki; Campillo-Calatayud, Ana; Les Bujanda, Íñigo (MDPI, 2024) Artículo / ArtikuluaSeveral factors have been associated with the occurrence of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) therapy. Despite their availability, the predictive value of circulating blood ... -
PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer
Bocanegra Gondán, Ana Isabel; Fernandez Hinojal, Gonzalo; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Garcia-Granda, María Jesús; Hernandez, Carlos; Ibáñez-Vea, María ; Hernandez-Marin, Berta; Martinez-Aguillo, Maite; Lecumberri, María José; Fernández de Lascoiti, Ángela; Teijeira, Lucía; Morilla Ruiz, Idoia; Vera García, Ruth; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2019) Artículo / ArtikuluaPD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade anticancer therapies, particularly for lung cancer. However, the reliability of this marker is still under debate. Moreover, ...